Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 26, 2010

Genentech Acquires Preclinical Human IL-17 mAb from NovImmune

  • Genentech has acquired exclusive rights to a fully human IL-17 mAb from NovImmune, along with access to back-up antibodies. NovImmune claims the late preclinical-stage antibody could have applications as a therapeutic candidate against multiple autoimmune diseases. As part of the deal the firm will receive an up-front payment from Genentech in addition to clinical milestones and future sales royalties.

    NovImmune is dedicated to discovering and developing therapeutic mAbs for the treatment of immune-related disorders. The company’s pipeline includes candidates against type 1 diabetes, Crohn disease, transplantation-related conditions, and autoimmune/inflammatory diseases. Lead candidate NI-0401 is a fully human anti-CD3 mAb designed to bind and modulate the CD3 epsilon chain expressed on T cells. The product is currently in mid-late-stage trials for the treatment of type 1 diabetes, Crohn disease, and transplantation indications.

    A Phase II-stage anti-inflammatory mAb candidate NI-0801 is designed to bind specifically and selectively to the human chemokine IP-10 (CXCL10) and inhibit the interaction of IP-10 with its cognate receptor and glycosaminoglycans.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »